

Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss

Joely Kaufman-Janette¹; Steven Dayan²; Charles Boyd³; Nazanin Ashourian⁴; Jane Yoo⁵

¹Skin Associates of South Florida, Coral Gables, FL; ²Department of Otolaryngology, University of Illinois College of Medicine, Chicago, IL; ³BOYD Beauty, Birmingham, MI; ⁴Allergan Aesthetics, an AbbVie company, Irvine, CA; ⁵Icahn School of Medicine at Mount Sinai, New York, NY

OBJECTIVE

To determine patient facial aesthetic concerns related to GLP-1 agonist associated weight loss and current trends in treatment strategies

CONCLUSIONS



This large survey of HCPs in various specialties found that clinicians perceive midface volume loss to be the most impacted area of the face and neck in GLP-1 agonist-associated weight loss patients, followed by skin laxity and facial wrinkles/folds



The main aesthetic treatments used to address these concerns are hyaluronic acid and botulinum neurotoxins, frequently in that order



Nearly half of HCPs agreed that hyaluronic acid is the best treatment for addressing facial and/or neck concerns in the growing population of GLP-1-treated patients

For additional information or to obtain a PDF of this poster

Scan QR code or use the following link to download an electronic version of this presentation and other Allergan Aesthetics and AbbVie [year] [congress abbreviation] scientific presentations: [add link here for QR code]



QR code expiration: April 18, 2027

To submit a medical question, please visit www.abbviedinfo.com

Allergan Aesthetics, an AbbVie company, and the authors thank the participants, study sites, and investigators who participated in this clinical trial.

[Funder - "Allergan Aesthetics, an AbbVie company" or "AbbVie"] funded this trial and participated in the trial design, research, analysis, data collection, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. The authors thank [name for acknowledgements] of [AbbVie or affiliation] for [add brief statement of contribution]. Medical writing support was provided by [name, degree] of [AbbVie or agency name].

Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: J. Kaufman-Janette is a clinical investigator/researcher for AbbVie, Croma, Evolus, Galderma, Jetera, Revance, and Teoxane and is on the speaker's bureau for Galderma. S. Dayan is a researcher, consultant, and/or speaker for AbbVie. C. Boyd is a primary investigator and speaker for Allergan Aesthetics, Galderma, and Rion. N. Ashourian is an employee of AbbVie and may own AbbVie stock. J. Yoo has no relevant disclosures.

INTRODUCTION

Background


- The weight loss that patients experience with glucagon-like peptide-1 (GLP-1) receptor agonists often impacts facial appearance by reducing facial fat volume, leading to wrinkles, sagging skin, and a gaunt appearance
- We sought to determine patient facial aesthetic concerns related to GLP-1 agonist associated weight loss and current trends in treatment strategies.

RESULTS

HCP Participant Characteristics


- Among HCPs invited to participate in the study, 2669 clicked on the survey link, 1483 did not qualify, 780 qualified but did not complete the survey, and 406 qualified and completed the survey

Total HCPs	N = 406
Dermatologists	n = 100
Plastic surgeons	n = 100
Other physicians/dentists	n = 105
Nurses/PAs	n = 101



- Years in Practice: 2-40 (mean = 14.4 years)
- Cosmetic patients treated per year: mean = 1249

Face Or Neck Areas Are Most Impacted By GLP-1 Agonists



Clinicians perceptions [% noting in top 3]; *such as nasolabial folds and marionette lines; **including tear troughs


Q: What areas of the face and/or neck are most impacted in GLP-1 patients?

METHODS

Design


- Data were obtained from an electronic survey of healthcare providers (HCPs) in the US with experience treating patients for aesthetic concerns following treatment with GLP-1 agonists
- HCPs in the relevant speciality areas who were part of independent, third-party databases were invited to take the survey and received compensation for their participation
- The survey was available from 28 March - 14 April 2025

Estimated Number of Patients Receiving GLP-1 Agonists Increased Across All HCP Speciality Groups From 2023 to 2024



Q: To the best of your knowledge, how many of your patients in [year] used GLP-1 medications (either prescribed by you or another clinician)?

Multimodal Care Is Common But No Clear Treatment Sequence



Q: What percent of your GLP-1 patients receiving non-surgical aesthetic treatments receive more than one type of aesthetic treatment?